Additionally, experimental studies in nude mice revealed that when combined with the AKR1B10 inhibitor epalrestat, sorafenib's inhibitory effects on HCC xenograft were enhanced 12. This evidence concerns the gene AKR1B10 and hepatocellular carcinoma.